Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

UroGen Pharma (URGN) Return on Capital Employed: 2017-2025

Historic Return on Capital Employed for UroGen Pharma (URGN) over the last 8 years, with Sep 2025 value amounting to -0.86%.

  • UroGen Pharma's Return on Capital Employed fell 54.00% to -0.86% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.86%, marking a year-over-year decrease of 54.00%. This contributed to the annual value of -0.52% for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Return on Capital Employed is -0.86%, which was down 26.10% from -0.68% recorded in Q2 2025.
  • UroGen Pharma's Return on Capital Employed's 5-year high stood at -0.32% during Q3 2024, with a 5-year trough of -1.31% in Q1 2021.
  • For the 3-year period, UroGen Pharma's Return on Capital Employed averaged around -0.58%, with its median value being -0.48% (2025).
  • Per our database at Business Quant, UroGen Pharma's Return on Capital Employed surged by 59bps in 2022 and then crashed by 54bps in 2025.
  • Quarterly analysis of 5 years shows UroGen Pharma's Return on Capital Employed stood at -0.88% in 2021, then climbed by 15bps to -0.73% in 2022, then surged by 31bps to -0.42% in 2023, then climbed by 3bps to -0.39% in 2024, then plummeted by 54bps to -0.86% in 2025.
  • Its Return on Capital Employed was -0.86% in Q3 2025, compared to -0.68% in Q2 2025 and -0.48% in Q1 2025.